Clinical significance of ADAM29 promoting the invasion and growth of gastric cancer cells in vitro

Chen,Hongbing; Wang,Siping

doi:10.3892/ol.2018.8838

Clinical significance of ADAM29 promoting the invasion and growth of gastric cancer cells in vitro

Authors:
- Hongbing Chen
- Siping Wang
View Affiliations

Affiliations: Department of Gastrointenstinal Surgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, P.R. China, Department of Emergency, Yantaishan Hospital, Yantai, Shandong 264001, P.R. China
Published online on: May 30, 2018 https://doi.org/10.3892/ol.2018.8838
Pages: 1483-1490
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

ADAM metallopeptidase domain 29 (ADAM29) belongs to the ADAM family, is a type I integral membrane protein and secrets a glycoprotein that mediates cell‑cell and cell‑matrix interaction. Aberrant expression of ADAM29 is involved in a number of physiological processes diversification. The purpose of the present study was to investigate the expression and biological effect of ADAM29 in human gastric cancer (GC) specimens and cell lines in vitro. The expression of ADAM29 was examined in 83 GC samples and 25 adjacent normal gastric tissues using quantitative reverse transcriptase‑quantitative polymerase chain reaction and immunohistochemistry. The association between ADAM29 expression and cellular function of GC cells was assessed in vitro. The ADAM29 mRNA levels were significantly elevated in GC tissues compared with paracancerous tissues. Increased levels of ADAM29 were associated with high‑grade staging and high Tumor‑Node‑Metastasis stages. Kaplan‑Meier survival curves demonstrated that patients with GC and low ADAM29 transcript levels exhibited longer overall survival (OS) (P<0.01) and progression‑free survival (PFS) time (P<0.01) compared with patients with high ADAM29 expression levels. ADAM29 significantly promoted the proliferation, migration and invasion of GC cells in vitro when overexpressed in MGC803 cells and knocked down in AGS cells. ADAM29 was increased in GC and the elevated expression of ADAM29 was associated with a poor survival rate of patients. ADAM29 may become a prognostic factor and therapeutic candidate for human GC.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
2	Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
3	Hu Y, Huang C, Sun Y, Su X, Cao H, Hu J, Xue Y, Suo J, Tao K, He X, et al: Morbidity and mortality of laparoscopic versus open D2 distal gastrectomy for advanced gastric cancer: A randomized controlled trial. J Clin Oncol. 34:1350–1357. 2016. View Article : Google Scholar : PubMed/NCBI
4	Irani S, Baron T, Itoi T and Khashab M: Endoscopic gastroenterostomy: Techniques and review. Curr Opin Gastroenterol. 33:320–329. 2017. View Article : Google Scholar : PubMed/NCBI
5	Zhu T, Hu X, Wei P and Shan G: Molecular background of the regional lymph node metastasis of gastric cancer. Oncol Lett. 15:3409–3414. 2018.PubMed/NCBI
6	Walkiewicz K, Gętek M, Muc-Wierzgoń M, Kokot T and Nowakowska-Zajdel E: The importance of ADAM family proteins in malignant tumors. Postepy Hig Med Dosw (Online). 70:67–73. 2016.(In Polish). View Article : Google Scholar : PubMed/NCBI
7	Brown RV, Gaerig VC, Simmons T and Brooks TA: Helping Eve overcome ADAM: G-quadruplexes in the ADAM-15 promoter as new molecular targets for breast cancer therapeutics. Molecules. 18:15019–15034. 2013. View Article : Google Scholar : PubMed/NCBI
8	Pham D, Kim J, Kim S, Shin D, Uong N, Hyun H, Yoon MS, Kang SJ, Ryu YJ, Cho JS, et al: Effects of ADAM10 and ADAM17 inhibitors on natural killer cell expansion and antibody-dependent cellular cytotoxicity against breast cancer cells in vitro. Anticancer Res. 37:5507–5513. 2017.PubMed/NCBI
9	Edwards DR, Handsley MM and Pennington CJ: The ADAM metalloproteinases. Mol Aspects Med. 29:258–289. 2008. View Article : Google Scholar : PubMed/NCBI
10	Qin H, Diaz A, Blouin L, Lebbink R, Patena W, Tanbun P, LeProust EM, McManus MT, Song JS and Ramalho-Santos M: Systematic identification of barriers to human iPSC generation. Cell. 158:449–461. 2014. View Article : Google Scholar : PubMed/NCBI
11	Nyren-Erickson E, Jones J, Srivastava D and Mallik S: A disintegrin and metalloproteinase-12 (ADAM12): Function, roles in disease progression, and clinical implications. Biochim Biophys Acta. 1830:4445–4455. 2013. View Article : Google Scholar : PubMed/NCBI
12	Wolfsberg T, Straight P, Gerena R, Huovila A, Primakoff P, Myles D and White JM: ADAM, a widely distributed and developmentally regulated gene family encoding membrane proteins with a disintegrin and metalloprotease domain. Dev Biol. 169:378–383. 1995. View Article : Google Scholar : PubMed/NCBI
13	Ohtsuka T, Shiomi T, Shimoda M, Kodama T, Amour A, Murphy G, Ohuchi E, Kobayashi K and Okada Y: ADAM28 is overexpressed in human non-small cell lung carcinomas and correlates with cell proliferation and lymph node metastasis. Int J Cancer. 118:263–273. 2006. View Article : Google Scholar : PubMed/NCBI
14	Le Pabic H, Bonnier D, Wewer U, Coutand A, Musso O, Baffet G, Clément B and Théret N: ADAM12 in human liver cancers: TGF-beta-regulated expression in stellate cells is associated with matrix remodeling. Hepatology. 37:1056–1066. 2003. View Article : Google Scholar : PubMed/NCBI
15	Yin H, Zhong F, Ouyang Y, Wang Q, Ding L and He S: Upregulation of ADAM12 contributes to accelerated cell proliferation and cell adhesion-mediated drug resistance (CAM-DR) in Non-Hodgkin's Lymphoma. Hematology. 22:527–535. 2017. View Article : Google Scholar : PubMed/NCBI
16	Xu M, Zhou H, Zhang C, He J, Wei H, Zhou M, Lu Y, Sun Y, Ding JW, Zeng J, et al: ADAM17 promotes epithelial-mesenchymal transition via TGF-β/Smad pathway in gastric carcinoma cells. Int J Oncol. 49:2520–2528. 2016. View Article : Google Scholar : PubMed/NCBI
17	Cerretti D, DuBose R, Black R and Nelson N: Isolation of two novel metalloproteinase-disintegrin (ADAM) cDNAs that show testis-specific gene expression. Biochem Biophys Res Commun. 263:810–815. 1999. View Article : Google Scholar : PubMed/NCBI
18	Song Y, Li L, Ou Y, Gao Z, Li E, Li X, Zhang W, Wang J, Xu L, Zhou Y, et al: Identification of genomic alterations in oesophageal squamous cell cancer. Nature. 509:91–95. 2014. View Article : Google Scholar : PubMed/NCBI
19	Wei X, Moncada-Pazos A, Cal S, Soria-Valles C, Gartner J, Rudloff U and Lin JC; NISC Comparative Sequencing Program; Rosenberg SA, López-Otín C and Samuels Y: Analysis of the disintegrin-metalloproteinases family reveals ADAM29 and ADAM7 are often mutated in melanoma. Hum Mutat. 32:E2148–E2175. 2011. View Article : Google Scholar : PubMed/NCBI
20	Zhang B, Li Y, Li L, Chen M, Zhang C, Zuo X, Zhou FS, Liang B, Zhu J, Li P, et al: Association study of susceptibility loci with specific breast cancer subtypes in Chinese women. Breast Cancer Res Treat. 146:503–514. 2014. View Article : Google Scholar : PubMed/NCBI
21	Purrington K, Slager S, Eccles D, Yannoukakos D, Fasching P, Miron P, Carpenter J, Chang-Claude J, Martin NG, Montgomery GW, et al: Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis. 35:1012–1019. 2014. View Article : Google Scholar : PubMed/NCBI
22	Zhao M, Jia W, Jiang W, Wang P, DU G, Cheng S and Song M: ADAM29 expression in human breast cancer and its effects on breast cancer cells in vitro. Anticancer Res. 36:1251–1258. 2016.PubMed/NCBI
23	Brim H, Abu-Asab M, Nouraie M, Salazar J, Deleo J, Razjouyan H, Mokarram P, Schaffer AA, Naghibhossaini F and Ashktorab H: An integrative CGH, MSI and candidate genes methylation analysis of colorectal tumors. PloS One. 9:e821852014. View Article : Google Scholar : PubMed/NCBI
24	Ashktorab H, Schäffer A, Daremipouran M, Smoot D, Lee E and Brim H: Distinct genetic alterations in colorectal cancer. PloS One. 5:e88792010. View Article : Google Scholar : PubMed/NCBI
25	Costa N, Paulo P, Caffrey T, Hollingsworth M and Santos-Silva F: Impact of MUC1 mucin downregulation in the phenotypic characteristics of MKN45 gastric carcinoma cell line. PloS One. 6:e269702011. View Article : Google Scholar : PubMed/NCBI
26	Kim SG and Hwang SH: The association between the duration of fluoropyrimidine-based adjuvant chemotherapy and survival in stage II or III gastric cancer. World J Surg Oncol. 14:1022016. View Article : Google Scholar : PubMed/NCBI
27	Yu H, Ye L, Mansel RE, Zhang Y and Jiang WG: Clinical implications of the influence of Ehm2 on the aggressiveness of breast cancer cells through regulation of matrix metalloproteinase-9 expression. Mol Cancer Res. 8:1501–1512. 2010. View Article : Google Scholar : PubMed/NCBI
28	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
29	Micocci KC, Moritz MN, Lino RL, Fernandes LR, Lima AG, Figueiredo CC, Morandi V and Selistre-de-Araujo HS: ADAM9 silencing inhibits breast tumor cells transmigration through blood and lymphatic endothelial cells. Biochimie. 128–129:174–182. 2016. View Article : Google Scholar
30	Mężyk-Kopeć R, Wyroba B, Stalińska K, Próchnicki T, Wiatrowska K, Kilarski WW, Swartz MA and Bereta J: ADAM17 promotes motility, invasion, and sprouting of lymphatic endothelial cells. PLoS One. 10:e01326612015. View Article : Google Scholar : PubMed/NCBI
31	Motycková M, Zák P, Vroblová V, Andrýs C, Belada D, Malý J and Smolej L: Prognostic markers in chronic lymphocytic leukemia. Vnitr Lek. 57:847–857. 2011.PubMed/NCBI